ViCardia

ViCardia is a biotechnology startup founded in 2017, with a primary focus on addressing heart failure through innovative therapies that target mitochondrial dysfunction. The company boasts a proficient leadership team, board of directors, and scientific advisory board, all with substantial experience in treating chronic and acute heart failure and conducting crucial cardiovascular research. With its dedication to discovering, developing, and commercializing advanced therapies for heart failure, particularly those related to mitochondrial dysfunction, ViCardia stands at the forefront of driving evolution in heart health. The company operates primarily within the Biotechnology and Health Care industries, positioning itself as a pioneering force in transforming treatment methodologies for heart-related ailments. Although specific details regarding its last investment, investors, and headquarters are currently undisclosed, ViCardia's relentless commitment to innovation and expertise in the field render it an intriguing prospect for potential venture capital investors seeking opportunities in the biotechnology and health care sectors.